Context Therapeutics (NASDAQ:CNTX) Downgraded to Sell Rating by Wall Street Zen

Context Therapeutics (NASDAQ:CNTX) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Several other equities analysts have also weighed in on CNTX. D. Boral Capital reiterated a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a report on Tuesday, March 24th. Piper Sandler upped their target price on shares of Context Therapeutics from $4.00 to $7.00 and gave the stock an “overweight” rating in a report on Tuesday, March 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a report on Monday, April 20th. Guggenheim restated a “buy” rating and issued a $5.00 target price on shares of Context Therapeutics in a report on Tuesday, March 24th. Finally, Lifesci Capital upgraded shares of Context Therapeutics to a “strong-buy” rating in a report on Monday, February 23rd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.60.

Context Therapeutics Trading Down 13.8%

Shares of NASDAQ CNTX opened at $1.75 on Friday. The firm’s 50-day moving average price is $2.45 and its 200-day moving average price is $2.08. Context Therapeutics has a 1-year low of $0.55 and a 1-year high of $3.62. The firm has a market capitalization of $160.79 million, a P/E ratio of -4.17 and a beta of 1.61.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.03. Equities research analysts forecast that Context Therapeutics will post -0.35 EPS for the current year.

Institutional Investors Weigh In On Context Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP grew its position in Context Therapeutics by 7,153.7% in the 4th quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock worth $3,812,000 after purchasing an additional 2,557,448 shares in the last quarter. Vanguard Group Inc. grew its position in Context Therapeutics by 4.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after purchasing an additional 134,449 shares in the last quarter. Renaissance Technologies LLC grew its position in Context Therapeutics by 58.8% in the 4th quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock worth $747,000 after purchasing an additional 188,202 shares in the last quarter. State Street Corp grew its position in Context Therapeutics by 8.5% in the 4th quarter. State Street Corp now owns 165,607 shares of the company’s stock worth $243,000 after purchasing an additional 13,000 shares in the last quarter. Finally, XTX Topco Ltd grew its position in Context Therapeutics by 858.8% in the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock worth $149,000 after purchasing an additional 91,008 shares in the last quarter. 14.03% of the stock is owned by institutional investors.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.